ProCE Banner Activity

Latest Developments and Insights on ADCs for Lung Cancer

Clinical Thought

Explore international expert insights on key questions on the latest developments with HER2-, HER3-, TROP2-, and B7-H3–targeted ADCs for lung cancer.

Released: November 05, 2024

Expiration: November 04, 2025

Share

Faculty

David Planchard

David Planchard, MD, PhD

Head of Thoracic Cancer Group
Department of Medical Oncology
Gustave Roussy
Villejuif, France

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc.

Disclosure

Primary Author

David Planchard, MD, PhD

Head of Thoracic Cancer Group
Department of Medical Oncology
Gustave Roussy
Villejuif, France

David Planchard, MD, PhD: consultant/advisor/speaker: AbbVie, ArriVent, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Janssen, Lilly, Merck, Mirati, Novartis, Pfizer, Pierre Fabre, Roche, Seagen, Takeda.